DermaSensor

Big news in sun protection: the FDA has approved the first new sunscreen active ingredient in over 20 years.

Bemotrizinol provides broad-spectrum protection against both UVA and UVB rays with low skin absorption, marking an important step forward for sunscreen innovation in the U.S.

While better sunscreen options matter, prevention and early detection still go hand in hand.

Protect your skin daily, reapply sunscreen as directed, and get suspicious spots checked by a healthcare professional.

For providers, having the right tools can help support faster, more confident skin cancer assessments at the point of care.

Learn more about DermaSensor at dermasensor.com.

source: allure.com

The way providers evaluate suspicious skin lesions is evolving.

DermaSensor™ was designed to bring AI-powered, non-invasive skin cancer risk assessment into real-world clinical workflows, helping support faster, more objective evaluations during the patient visit.

Backed by clinical evidence, built for everyday practice, and designed to fit naturally into modern healthcare settings.

See why more providers are exploring DermaSensor™ and request a demo at dermasensor.com.